Lisavanbulin

DB15224InvestigationalSmall molecule

Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).

Mechanism: Pharmacologically active on Tubulin
Curator reviewed
Formula / weight: C₂₆H₂₉N₉O₃ · 515.578 g/mol (avg)
Code names: BAL101553

Resolves to

Compound

UNII5PT0QP06X5CAS1263384-43-5

Structure

InChIKeyNIPZLALJRAHABJ-IBGZPJMESA-NSMILESNCCCC[C@H](N)C(=O)NC1=CC=C(C=C1)C(=O)CN1C2=C(C=CC=C2)N=C1C1=NON=C1NCCC#N

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Lisavanbulin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account